Table 5. Number of adolescents with clinical symptoms observed prior to treatment and adverse events in the S. haematobium study among the four different treatment arms, assessed at different time points.
The study was carried out in the villages of Moronou, Bigouin and Biakalé in central Côte d’Ivoire, between May and June 2015.
| Evaluation time points | Moxidectin (N = 31) | Synriam plus praziquantel (N = 32) | Synriam (N = 33) | Praziquantel (N = 32) | Overall (n = 128) |
|---|---|---|---|---|---|
| Clinical symptoms before treatment | 31 (100.0) | 32 (100.0) | 33 (100.0) | 32 (100.0) | 128 (100.0) |
| 3 hours after first treatment | 14 (45.0) | 13 (41.0) | 17 (52.0) | 18 (58.0) | 62 (48.4) |
| 24 hours after first treatment | 9 (29.0) | 9 (28.0) | 4 (12.0) | 6 (19.0) | 28 (21.8) |
| 72 hours after first treatment | 7 (23.0) | 9 (28.0) | 6 (18.0) | 5 (16.0) | 27 (21.1) |
| 3 hours after second treatment | NA | 3 (9.0) | 1 (3.0) | NA | 4/65 (6.2) |
| 24 hours after second treatment | NA | 1 (3.0) | 0 (0) | NA | 1/65 (1.5) |
| 72 hours after second treatment | NA | 0 (0) | 0 (0) | NA | 0/65 (0) |
| 3 hours after third treatment | NA | 1 (3.0) | 0 (0) | NA | 1/65 (1.5) |
| 24 hours after third treatment | NA | 1 (3.0) | 0 (0) | NA | 1/65 (1.5) |
| 72 hours after third treatment | NA | 0 (0) | 0 (0) | NA | 0/65 (0) |